EVAX

Evaxion Biotech AS

(NO DISGNOSTIC SUBSTANCES)
LIFE SCIENCES

Prices are adjusted according to historical splits.

Evaxion Biotech AS Stock Price

Vitals

Today's Low:
$2.5000
Today's High:
$2.6000
Open Price:
$2.6000
52W Low:
$1.51
52W High:
$7.73
Prev. Close:
$2.5000
Volume:
15750

Company Statistics

Market Cap.:
$0.061 billion
Book Value:
0.845
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-53.3%
Return on Equity TTM:
-115.2%

Company Profile

Evaxion Biotech AS had its IPO on 2021-02-05 under the ticker symbol EVAX.

The company operates in the LIFE SCIENCES sector and (NO DISGNOSTIC SUBSTANCES) industry. Evaxion Biotech AS has a staff strength of 0 employees.

Stock update

Shares of Evaxion Biotech AS opened at $2.6 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $2.5 - $2.6, and closed at $2.54.

This is a +1.6% increase from the previous day's closing price.

A total volume of 15,750 shares were traded at the close of the day’s session.

In the last one week, shares of Evaxion Biotech AS have slipped by -15.33%.

Evaxion Biotech AS's Key Ratios

Evaxion Biotech AS has a market cap of $0.061 billion, indicating a price to book ratio of 3.094 and a price to sales ratio of -.

In the last 12-months Evaxion Biotech AS’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.026 billion. The EBITDA ratio measures Evaxion Biotech AS's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Evaxion Biotech AS’s operating margin was 0% while its return on assets stood at -53.3% with a return of equity of -115.2%.

In Q2, Evaxion Biotech AS’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Evaxion Biotech AS’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-1.259 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evaxion Biotech AS’s profitability.

Evaxion Biotech AS stock is trading at a EV to sales ratio of - and a EV to EBITDA ratio of -1.954. Its price to sales ratio in the trailing 12-months stood at -.

Evaxion Biotech AS stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Evaxion Biotech AS ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Evaxion Biotech AS ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Evaxion Biotech AS’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Evaxion Biotech AS's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Evaxion Biotech AS paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$2.54
52-Week High
$7.73
52-Week Low
$1.51
Analyst Target Price
$15.5

Evaxion Biotech AS stock is currently trading at $2.54 per share. It touched a 52-week high of $7.73 and a 52-week low of $7.73. Analysts tracking the stock have a 12-month average target price of $15.5.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Evaxion Biotech AS

The stock symbol (also called stock or share ticker) of Evaxion Biotech AS is EVAX

The IPO of Evaxion Biotech AS took place on 2021-02-05

Similar Industry Stocks ((NO DISGNOSTIC SUBSTANCES))

Last Price
Chg
Chg%
Vaxcyte Inc (PCVX)
$42.52
-2.48
-5.51%
$1.07
0.02
+1.9%
$73.98
-2.93
-3.81%
$20.01
0
0%
$22.32
-0.2
-0.89%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Evaxion Biotech A / S, a clinical-stage artificial intelligence and immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company is headquartered in Hoersholm, Denmark.

Address

BREDGADE 34E, COPENHAGEN K, DK